2-[4-Chloro-6-[4-(4-cyanophenyl)anilino]pyrimidin-2-yl]sulfanyl-2-naphthalen-1-ylacetic acid | 1287678-06-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-Chloro-6-[4-(4-cyanophenyl)anilino]pyrimidin-2-yl]sulfanyl-2-naphthalen-1-ylacetic acid
• CAS: 1287678-06-1
• 化学式: C₂₉H₁₉ClN₄O₂S
• 分子量: 523.014
• InChiKey: ROSPVHMBKTUANF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  ethyl 2-[(4,6-dichloropyrimidin-2-yl)sulfanyl]-2-(naphthalene-1-yl)acetate 在 三乙胺 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-[4-Chloro-6-[4-(4-cyanophenyl)anilino]pyrimidin-2-yl]sulfanyl-2-naphthalen-1-ylacetic acid
  参考文献：
  名称：

  A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold

  摘要：

  Dual inhibition of microsomal prostaglandin E-2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO) represents a promising strategy in the development of novel anti-inflammatory drugs targeting the arachidonic acid cascade. Herein, a class of alpha-naphthyl pirinixic acids is characterized as dual mPGES-1/5-LO inhibitors. Systematic structural variation was focused on the lipophilic backbone of the scaffold and yielded detailed structure-activity relationships (SAR) with compound 16 (IC50 mPGES-1 = 0.94 mu M; IC50 5-LO = 0.1 mu M) showing the most favorable in vitro pharmacological profile. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.049

文献信息

• A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold
  作者：Martina Hieke、Christine Greiner、Theresa M. Thieme、Manfred Schubert-Zsilavecz、Oliver Werz、Heiko Zettl

  DOI：10.1016/j.bmcl.2011.01.049

  日期：2011.3

  Dual inhibition of microsomal prostaglandin E-2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO) represents a promising strategy in the development of novel anti-inflammatory drugs targeting the arachidonic acid cascade. Herein, a class of alpha-naphthyl pirinixic acids is characterized as dual mPGES-1/5-LO inhibitors. Systematic structural variation was focused on the lipophilic backbone of the scaffold and yielded detailed structure-activity relationships (SAR) with compound 16 (IC50 mPGES-1 = 0.94 mu M; IC50 5-LO = 0.1 mu M) showing the most favorable in vitro pharmacological profile. (C) 2011 Elsevier Ltd. All rights reserved.